Pain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study

Table 4 Multivariable regression (PsA participants)

	OR	95%CI	P		OR	95% CI	P
Age	1.02	0.98–1 05	0.32	Age	1.02	0.99–1.06	0.23
Sex	0.99	0.41—2.40	0.99	Sex	1.02	0.39–2.63	0.97
DAPSA	1.04	0.99–1 08	0.10	DAPSA	1.03	0.99–1 08	0.15
*PCS*	1.04	1.00–1.07	0.03	Rumination	1.10	1.02–1.20	0.02
CCS	1.98	0.78–4.99	0.15	CCS	1.99	0.76–5.20	0.16
Age	1.02	0.99–1.06	0.20	Age	1.02	0.98–1.06	0.26
Sex	1.17	0.47–2.94	0.72	Sex	1.29	0.53–3 14	0.58
DAPSA	1.03	0.98–1.08	0.20	DAPSA	1.04	1.00–1.09	0.04
*Helplessness*	1.09	1.01–1.18	0.03	Magnification	1.15	0.97–1.36	0.10
CCS	1.91	0.78–4.95	0.18	CCS	1.87	0.72–4.81	0.20

DAPSA Disease Activity in PSoriatic Arthritis, PCS Pain Catastrophizing Scale, CCS corticosteroids

ISSN: 1478-6362